Voluntis

The company develops software-as-a-medical-device (SaMD) solutions that empower patients with chronic conditions, such as diabetes and cancer, to self-manage their treatments. Voluntis' core offering is the Theraxium technology platform, which serves as the foundation for a variety of mobile and web applications. This platform utilizes clinical algorithms to provide personalized, real-time recommendations to patients for adjusting medication dosages, managing side effects, and monitoring symptoms, thereby facilitating better collaboration with their healthcare providers. The business model primarily revolves around licensing its Theraxium platform to biopharmaceutical companies. Revenue is generated through upfront payments, development milestones, and recurring per-patient license fees once the solutions are commercialized. Voluntis forges long-term partnerships with major life science companies to create digital companions for their drugs, aiming to enhance treatment efficacy and patient quality of life.

A significant milestone in the company's history was its acquisition by AptarGroup, Inc. in 2021. Aptar, a global leader in drug delivery systems, acquired a majority stake in Voluntis to expand its digital health portfolio, combining its connected device ecosystem with Voluntis' DTx platform. This strategic move was intended to enable the development of novel digital therapeutic solutions across a broader range of disease areas. Prior to the acquisition, Voluntis had already established itself as a front-runner in the DTx space, achieving multiple regulatory approvals in the US, Europe, and Canada and raising a total of $31.2 million in funding over three rounds. Keywords: digital therapeutics, SaMD, chronic disease management, patient empowerment, clinical algorithms, biopharma partnerships, medication adherence, oncology, diabetes, Theraxium platform